Skip to main content

Table 2 BRCA1/2 Mutations in Older Triple Negative Breast Cancer

From: Therapeutic landscape in mutational triple negative breast cancer

Reference Race/Ethnicity TNBC cases Total TNBC TNBC (>50 years) TNBC (>60 years)
BRCA1 prevalence BRCA2 prevalence BRCA1 prevalence BRCA2 prevalence BRCA1 prevalence BRCA2 prevalence
Comen 2011 [11] AJa 64 29.7% (19/64) 9.4% (6/64) 13.9% (5/36) 11.1% (4/36) _ _
Hartman 2012 [79] Caucasian/Hispanic/AAb/Asian 199 6.5% (13/199) 4.0% (8/199) 4.4% (5/113) 2.7% (3/113) _ _
Greenup 2013 [13] Caucasian/Hispanic/AA/Asian/AJ 450 23.5% (106/450) 7.1% (32/450) 14.9% (25/168) 7.7% (13/168) 5.3% (2/38) 7.9% (3/38)
Sharma 2014 [80] Caucasian/AA/AJ 207 11.1% (23/207) 4.3% (9/207) BRCA1/2 prevalence 8.4%(11/131) BRCA1/2 prevalence 4.9%(3/62)
Couch 2015 [6] Caucasian/Hispanic/AA/Asian 1824 8.5% (155/1824) 2.7% (49/1824) 3.3% (17/520) 1.3% (7/520) 1.4% (4/279) 0.7% (2/279)
Wong 2015 [82] Australian 439 5.9% (26/439) 3.4% (15/439) 2.1% (6/286) 3.5% (10/286) 2.2% (4/182) 2.2% (4/182)
Wong 2015 [82] Polish 335 5.4% (18/335) 4.5% (15/335) 3.5% (10/286) 4.5% (13/286) 2.1% (3/141) 4.3% (6/141)
Gonzalez 2016 [83] Caucasian/Hispanic/AA/Asian 105 12.4% (13/105) 1.9% (2/105) 3.8% (2/52) 1.9% (1/52) _ _
Zhang 2016 [84] Chinese 990 7.2% (71/990) 2.2% (22/990) 3.7% (18/492) _ _ _
  1. Abbreviations: a Ashkenazi Jewish; b African American